BMC Gastroenterology
Cure8 research brief
Why This Matters
Extrapulmonary TB can be triggered or revealed during immunosuppressive biologic therapy and may mimic other causes of liver injury; early recognition and TB-specific testing are important for timely treatment and to guide UC management.
Who Should Pay Attention
Adult patients with IBD on or considering biologic therapy (especially anti-TNF agents), clinicians prescribing or monitoring biologics, and caregivers concerned about infection risks.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthMetadata only
What To Know
A 55-year-old man with long-standing UC received vedolizumab then switched to infliximab for steroid-dependent severe disease. After six infliximab doses he developed fever and imaging showed liver and spleen nodules.
Diagnostic testing (positive T-SPOT/PPD, granulomatous biopsy, and Xpert MTB/RIF) confirmed hepatic/splenic TB and anti-tuberculosis treatment was started. The report notes guideline recommendations for baseline TB screening (PPD, T-SPOT, chest CT) and regular surveillance while on biologics, and that extrapulmonary TB may require long (≥12 months) therapy.
Keep In Mind
Guidelines recommend baseline TB screening (PPD/T-SPOT and chest imaging) before starting biologics and periodic surveillance during treatment. This report underscores that sequential biologic exposure may increase complexity and that extrapulmonary TB can present insidiously.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationBMC Gastroenterology
PublisherSpringer Science and Business Media LLC
AuthorsShuo Chen, Yanfen Shi, Yang Pang +3 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 16, 2026, 12:00 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
Crohn's Disease Clinical Trials And Studies 2025: EMA, PDMA, FDA Approvals, Mechanism ...
This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...
Do You Need to Treat Asymptomatic Crohn’s Disease?
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.